March 6, 2018
Italian Fine Foods & Pharmaceuticals to use OptiBiotix Health’s LPLDL
OptiBiotix Health has bagged a deal with Italian Fine Foods & Pharmaceuticals N.T.M. S.p.A in which it allows Fine Foods…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
March 5, 2018
Santhera’s study shows safety profile of idebenone at higher dose than now approved for Raxone in Leber’s hereditary optic neuropathy
An investigator-initiated trial at the National Institutes of Health (NIH) in an exploratory Phase I/II clinical trial in primary progressive…
March 5, 2018
Evgen Pharma remains focused on clinical development of SFX-01, commit to explore therapeutic potential of novel sulforaphane analogues
The results of an evaluation of Evgen Pharma’s novel sulforaphane analogues suggest that some of the analogues merit further study as…
March 5, 2018
Artios, Masaryk in in-licensing deal for DNA nucleases targeting drug development
Artios Pharma has exercised its option to in-license the first nuclease drug development with Masaryk University in the Czech Republic,…
March 5, 2018
Abzena settles with Stanford University over claims against PacificGMP
Abzena has settled with Stanford University about the claims against PacificGMP.
March 2, 2018
BMS welcomes new Board member
Bristol-Myers Squibb’s Board of Directors has elected José Baselga, M.D., Ph.D., to the Board, effective March 1, 2018. Dr. Baselga will…
March 1, 2018
(EDITED) Vertex kicks off phase 3 trial of triple combination regimen for people with the most common genetic form of Cystic Fibrosis
Edit: The first paragraph used to say: Vertex is conducting the global ECLIPSE Phase 3 clinical trial program to evaluate VX-659…
March 1, 2018
Novavax plans Phase 2 trial of NanoFlu vaccine in third quarter of 2018
NanoFlu vaccine was well tolerated over the three-week trial period, Novavax said Thursday, adding it now expects to begin a…
March 1, 2018
Amarin Corporation’s cardiovascular study is nearing completion
Amarin Corporation’s REDUCE-IT cardiovascular study is nearing end, as the patients enrolled in it have begun the final study-related visits.
March 1, 2018
Basilea Pharmaceutica names Kaul as its Management Committee’s Chief Development Officer
Basilea Pharmaceutica has named Adesh Kaul as its Management Committee’s Chief Corporate Development Officer, who has been leading partnering activities…